Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
Actively Recruiting
Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of datopotamab deruxtecan Dato-DXd compared with docetaxel in patients who have advanced or metastatic non-squamous non-small cell lung cancer NSCLC that is positive for trophoblast cell surface protein 2 TROP2 and lacks actionable genomic alterations. This phase III study is randomized, open-label, and includes two groups to compare these treatments in participants who have previously received therapy. Participants receive either Dato-DXd or docetaxel through intravenous infusions every three weeks, with each treatment given on the first day of a 21-day cycle. The study also evaluates the performance of an investigational diagnostic device that measures TROP2 levels. This two-arm study runs until disease progression or other discontinuation criteria are met. During the study, participants undergo regular assessments including imaging scans to measure tumor size, laboratory tests to check organ function, and questionnaires related to lung cancer symptoms, physical function, and quality of life. Researchers will monitor progression-free survival and overall survival over approximately 2.5 to 3.5 years, along with secondary outcomes such as response rates and duration of response. Safety and tolerability are also evaluated throughout the trial.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the combination of sapanisertib and serabelisib PIKTOR with paclitaxel in women with advanced or recurrent endometrial cancer. This Phase 2, open-label, single-arm study focuses on participants who have previously undergone systemic therapies, including platinum-based chemotherapy and immune checkpoint inhibitors, but whose cancer has not responded or returned. Participants will receive oral doses of sapanisertib and serabelisib together with intravenous paclitaxel. The study also includes a substudy that evaluates the combination of PIKTOR and paclitaxel with an insulin-suppressing diet. Treatment is administered under medical supervision at multiple centers. During the study, participants will undergo regular assessments to monitor tumor response, disease progression, survival, and treatment safety over extended periodsup to two years for response assessment and up to five years for survival and progression measures. Researchers will track adverse events and overall treatment tolerability. The total study duration and follow-up will allow detailed evaluation of treatment effects and participant health.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 combined with chemotherapy in people with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not received prior treatment for their advanced disease. This Phase 23 trial aims to evaluate the safety and effectiveness of PF-08634404 with chemotherapy compared to an approved treatment nivolumab plus chemotherapy for this type of cancer. Participants receive PF-08634404 or nivolumab intravenously along with chemotherapy in repeated treatment cycles. The study has two parts the first part focuses on assessing safety and response to the study medicine combined with chemotherapy, while the second part compares the study medicine plus chemotherapy to nivolumab plus chemotherapy to see which treatment works better. During the trial, participants undergo medical tests to monitor safety, treatment response, and cancer progression using established criteria. Researchers measure outcomes such as objective response rate, progression-free survival, overall survival, and quality of life over approximately four years. Adverse events, laboratory results, and drug concentrations are also tracked throughout treatment and for 90 days after the last intervention.
Actively Recruiting
Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.